Title:
RECURRENCE PREVENTIVE THERAPEUTIC AGENT FOR PSYCHOSTIMULANT-INDUCED PSYCHOSIS AND SCHIZOPHRENIA
Document Type and Number:
WIPO Patent Application WO/2006/093192
Kind Code:
A1
Abstract:
Disclosed is a recurrence preventive therapeutic agent for psychostimulant-induced psychosis and schizophernia. The therapeutic agent comprises a substance capable of enhancing the signal transduction of serotonin as the active ingredient. The substance is preferably a selective serotonon reuptake inhibitor (SSRI) or a double serotonin-noradrenaline reuptake inhibitor (SNRI), since it can bind to a transporter capable of inhibiting the reuptake of serotonin in the synaptic gap to inhibit the uptake of serotonin.
Inventors:
KASHIWA ATSUSHI (JP)
NISHIKAWA TORU (JP)
KANEKO YUJIRO (JP)
NISHIKAWA TORU (JP)
KANEKO YUJIRO (JP)
Application Number:
PCT/JP2006/303883
Publication Date:
September 08, 2006
Filing Date:
March 01, 2006
Export Citation:
Assignee:
UNIV TOKYO MEDICAL & DENTAL (JP)
KASHIWA ATSUSHI (JP)
NISHIKAWA TORU (JP)
KANEKO YUJIRO (JP)
KASHIWA ATSUSHI (JP)
NISHIKAWA TORU (JP)
KANEKO YUJIRO (JP)
International Classes:
A61K45/00; A61K31/138; A61K31/4525; A61P25/18; A61P25/30
Other References:
PRZEGALINSKI E. ET AL.: "Activation of serotonin(5-HT)1A receptors inhibits amphetamine sensitization in mice", LIFE SCIENCES, vol. 66, no. 11, 2000, pages 1011 - 1019, XP003005893
UDA M. ET AL.: "The 5-HT1A receptor agonist MKC-242 reverses methamphetamine-induced behavioral sensitization in mice (P-10217)", JOURNAL OF PHARMACOLOGICAL SCIENCES, vol. 94, no. SUPPLEMENT 1, 2004, pages 176, XP003005894
AMANO T. ET AL.: "Alteration of neuronal activities following repeated administration of stimulants", JAPANESE JOURNAL OF ALCOHOL AND DRUG DEPENDENCE, vol. 37, no. 1, 2002, pages 31 - 40, XP003005895
BEERS M.H. AND BERKOW R.: "The Merck Manual", vol. 17E ED., 1999, MERCK RESEARCH LABORATORIES, pages: 1533, XP002215956
SILLS T.L. AND FLETCHER P.J.: "Fluoxetine attenuates morphine-induced locomotion and blocks morphine-sensitization", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 337, no. 2/3, 1997, pages 161 - 164, XP003005896
AUCLAIR A. ET AL.: "5-HT2A and alpha1b-adrenergic receptors entirely mediate dopamine release, locomotor response and behavioural sensitization to opiates and psychostimulants", EUROPEAN JOURNAL OF NEUROSCIENCE, vol. 20, 2004, pages 3073 - 3084, XP003005897
See also references of EP 1859807A4
UDA M. ET AL.: "The 5-HT1A receptor agonist MKC-242 reverses methamphetamine-induced behavioral sensitization in mice (P-10217)", JOURNAL OF PHARMACOLOGICAL SCIENCES, vol. 94, no. SUPPLEMENT 1, 2004, pages 176, XP003005894
AMANO T. ET AL.: "Alteration of neuronal activities following repeated administration of stimulants", JAPANESE JOURNAL OF ALCOHOL AND DRUG DEPENDENCE, vol. 37, no. 1, 2002, pages 31 - 40, XP003005895
BEERS M.H. AND BERKOW R.: "The Merck Manual", vol. 17E ED., 1999, MERCK RESEARCH LABORATORIES, pages: 1533, XP002215956
SILLS T.L. AND FLETCHER P.J.: "Fluoxetine attenuates morphine-induced locomotion and blocks morphine-sensitization", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 337, no. 2/3, 1997, pages 161 - 164, XP003005896
AUCLAIR A. ET AL.: "5-HT2A and alpha1b-adrenergic receptors entirely mediate dopamine release, locomotor response and behavioural sensitization to opiates and psychostimulants", EUROPEAN JOURNAL OF NEUROSCIENCE, vol. 20, 2004, pages 3073 - 3084, XP003005897
See also references of EP 1859807A4
Attorney, Agent or Firm:
Shobayashi, Masayuki (25-8 Higashi-ikebukuro 1-chome, Toshima-k, Tokyo 13, JP)
Download PDF: